Research Facts
Now being in lockdown and catching up on reading Yahoo finance tonight News
So 12 months of silence is broken , Be very interested in ANNS in Morning and Market reaction will be Today . This will be my last post on hotcopper been interesting but clearly Facts are lacking by many posters been a eduction .
So here it hot off the press enjoy Punters "Extract "
With this partnership The Valens Company continues its "revenue first, capital efficient" strategy of expanding internationally. As part of the Agreement with Epsilon and Cannvalate, Valens will be provided with access to Epsilon's GMP manufacturing capabilities at the Southport Facility (as defined below) located in Queensland, Australia, the largest cannabis manufacturing facility in the Southern Hemisphere, and the largest at domestic scale with complimentary Therapeutic Good Administration (TGA) and EU GMP capabilities. The partnership also marks the first GMP manufactured products to be sold through Valens in Australia, and provides Valens with the capability to deliver GMP-grade products to Latin America, Europe, UK and Asia-Pacific.Key Transaction Details:The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon's GMP Manufacturing Facility in Southport, Queensland Australia(the "Southport Facility')Epsilon's Southport Facility is the largest cannabis extraction facility in the Southern Hemisphere with TGA and EU GMP capabilityValens to fund all operational and capital expenditure of the Southport Facility in return for preferential access for up to 85 percent of the operational capacity of the Southport Facility over the next five years, with an option to extend this arrangement for an additional six yearsValens to provide operational and management consultancy at the Southport Facility to bring their industry-leading intellectual property, technology, and team to the Southport Facility to take advantage of Epsilon's GMP Manufacturing capabilityMarks first foray into EU GMP medicine production for ValensThe Agreement compliments its existing partnership with Cannvalate opening up GMP manufactured products to be sold through Cannvalate's distribution network First products manufactured under strategic alliance expected to be delivered in the coming weeksEpsilon's wholly owned subsidiary, THC Pharma Pty Ltd (THC Pharma) operates a TGA and Office of Drug Control (ODC) licensed medicinal cannabis manufacturing facility with TGA and EU GMP capabilities in Southport, Queensland Australia. THC Pharma's GMP Southport facility is a 10,000 square foot purpose-built botanicals extraction facility capable of extraction of raw plant material and downstream purification and isolation processing. The facility consists of its own QC lab and grade D cleanroom space for the manufacture of oral dose format products. Epsilon also owns a number of medicinal cannabis assets, including the Tetra Health clinic, and the Medimar Platform – an end-to-end ecommerce solution for nutraceuticals and cannabis. Epsilon also operates a turn-key cannabis cultivation solutions provider based in Vancouver, Canada.
There was a small team with shareholders that made this possible in the begin but are no more "Vanished without a trace" . John Hall , Andrew Beehag and Ken Charteris to name just a few , the licence , the Factory , permits the TGA and GMP Certificate and Australian (Bundaberg ) Crops for Canadeo MC all TGA/GMP sold to patients over 12 months ago .
Bang
Research Facts Now being in lockdown and catching up on reading...
Add to My Watchlist
What is My Watchlist?